Aravive To Present at The Cowen and Company 40th Annual Health Care Conference
February 25 2020 - 4:07PM
Aravive, Inc. (Nasdaq: ARAV), a clinical-stage biopharmaceutical
company, today announced that it will present at Cowen and
Company's 40th Annual Health Care Conference in Boston, MA.
Event: Cowen & Company 40th Annual Health Care
ConferencePresentation Date & Time: Tuesday, March 3, 2020,
8:00 AM ETLocation: New York, NY
A live webcast of the presentation will be available at
http://ir.aravive.com.
About AraviveAravive, Inc. (Nasdaq: ARAV) is a
clinical-stage biopharmaceutical company developing treatments
designed to halt the progression of life-threatening diseases,
including cancer and fibrosis. Aravive’s lead product candidate,
AVB-500, is an ultra-high affinity decoy protein that targets the
GAS6-AXL signaling pathway. By capturing serum GAS6, AVB-500
starves the AXL pathway of its signal, potentially halting the
biological programming that promotes disease progression. AXL
receptor signaling plays an important role in multiple types of
malignancies by promoting metastasis, cancer cell survival,
resistance to treatments, and immune suppression. The GAS6-AXL
signaling pathway also plays a significant role in fibrogenesis.
Aravive is evaluating AVB-500 in platinum-resistant ovarian cancer,
clear cell renal cell carcinoma (ccRCC) and kidney fibrosis and
intends to expand development into additional oncology and fibrotic
indications. Aravive is based in Houston, Texas and received a
Product Development Award from the Cancer Prevention & Research
Institute of Texas (CPRIT) in 2016. For more information, please
visit www.aravive.com.
Contacts:Investors: Christina TartagliaStern
Investor Relationschristina@sternir.com
Media: Heidi Chokeir, Ph.D.Canale
Communicationsheidi@canalecomm.com
Aravive (NASDAQ:ARAV)
Historical Stock Chart
From Aug 2024 to Sep 2024
Aravive (NASDAQ:ARAV)
Historical Stock Chart
From Sep 2023 to Sep 2024